Aservo EquiHaler

RSS

ciclesonide

Authorised
This medicine is authorised for use in the European Union.

Overview

Aservo Equihaler is an anti-inflammatory medicine used to treat severe asthma in horses. Aservo Equihaler contains the active substance ciclesonide.

This EPAR was last updated on 28/02/2020

Authorisation details

Product details
Name
Aservo EquiHaler
Agency product number
EMEA/V/C/004991
Active substance
ciclesonide
International non-proprietary name (INN) or common name
ciclesonide
Species
Horses
Anatomical therapeutic chemical veterinary (ATCvet) codes
QR03BA08
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
28/01/2020
Contact address

55216 Ingelheim am Rhein
Germany

Product information

Aservo EquiHaler - EMEA/V/C/004991 -

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Respiratory system

  • Other drugs for obstructive airway diseases, inhalants

Therapeutic indication

For the alleviation of clinical signs of severe equine asthma (formerly known as Recurrent Airway Obstruction – (RAO), Summer Pasture Associated Recurrent Airway Obstruction – (SPA-RAO)).

Assessment history

How useful was this page?

Add your rating